Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer.
Saved in:
| Title: | Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. |
|---|---|
| Authors: | Chigutsa E; Eli Lilly and Company, Indianapolis, Indiana, USA., Chapman SC; Eli Lilly and Company, Indianapolis, Indiana, USA., Turner PK; Eli Lilly and Company, Indianapolis, Indiana, USA. |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2026 Apr; Vol. 119 (4), pp. 1070-1079. Date of Electronic Publication: 2026 Jan 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41589906 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Chigutsa+E%22">Chigutsa E</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Chapman+SC%22">Chapman SC</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Turner+PK%22">Turner PK</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220372741%22">Clinical pharmacology and therapeutics</searchLink> [Clin Pharmacol Ther] 2026 Apr; Vol. 119 (4), pp. 1070-1079. <i>Date of Electronic Publication: </i>2026 Jan 27. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372741 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-6535 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200099236%22">00099236 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41589906 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cpt.70212 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1070 Titles: – TitleFull: Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chigutsa E – PersonEntity: Name: NameFull: Chapman SC – PersonEntity: Name: NameFull: Turner PK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2026 Apr Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1532-6535 Numbering: – Type: volume Value: 119 – Type: issue Value: 4 Titles: – TitleFull: Clinical pharmacology and therapeutics Type: main |
| ResultId | 1 |
